Cleveland BioLabs(NASDAQ:CBLI) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $989.665K. Analysts estimated a revenue of $7.880M. The revenues were -87.44% below the estimates. Earnings per share were $-0.11.
Cleveland BioLabs (CBLI) shares turned negative on Wednesdays trading session with the shares closing down -0.19 points or -9.69% at a volume of 39,336. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.96. The peak price level was also seen at $1.96 while the days lowest was $1.71. Finally the shares closed at $1.77. The 52-week high of the shares is $3.68 while the 52-week low is $1.22. According to the latest information available, the market cap of the company is $19 M.
Several Insider Transactions has been reported to the SEC. On Feb 27, 2015, Randy S. Saluck (director) purchased 1,891 shares at $3.42 per share price.
Cleveland BioLabs Inc. (CBLI) is a biopharmaceutical company. The Companys programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act through mechanisms and targets to kill cancer and protect healthy cells. The Companys lead product candidates include Entolimod which is designed for biodefense indication and as an oncology drug and Curaxin CBL0137 a lead oncology product candidate. The Companys products include Entolimod (CBLB502) Biodefense Entolimod (CBLB502) Oncology CBLB612 CBLC102 and CBLC137 Revercom Mobilan Arkil Antimycon and Xenomycins. The Companys subsidiaries include Incuron LLC which develops product candidates CBL0102 and CBL0137 for oncology indications; and Panacela which develops new preclinical product candidates primarily focused in oncology.